View on Pubmed.gov 42174362 | View on doi.org 10.1007/s12072-...
Phosphatidylethanol versus clinical criteria to diagnose alcohol use relapse after liver transplantation: a prospective cohort study.
- HEGITO - Div Hepatology, Gastroenterology and Liver Transplant, Dept. Internal Medicine 2, Faculty of Medicine, Slovak Medical University, F. D. Roosevelt University Hospital, Banska Bystrica, Slovakia.
- 2nd Department of Internal Medicine, L. Pasteur University Hospital and PJ Safarik University, Kosice, Slovakia.
- HEGITO - Div Hepatology, Gastroenterology and Liver Transplant, Dept. Internal Medicine 2, Faculty of Medicine, Slovak Medical University, F. D. Roosevelt University Hospital, Banska Bystrica, Slovakia. sselcanova@gmail.com.
- SK-LAB, s.r.o. - Clinical Laboratory, Lucenec, Slovakia.
- Sanatorium AT, Specialized Psychotherapeutic Treatment Facility, Bratislava, Slovakia.
- Gastroenterology and Hepatology Subdivision, 5th Department of Internal Medicine, Comenius University Faculty of Medicine, University Hospital Bratislava, Bratislava, Slovakia.
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, USA.
- Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Abstract
BACKGROUND
Alcohol-associated liver disease (ALD) with concomitant alcohol use disorder (AUD) is a leading indication for liver transplantation (LT). Return to alcohol use after LT (RAULT) affects a considerable proportion of recipients but lacks an objective diagnostic standard. We evaluated blood phosphatidylethanol (PEth) as a direct biomarker of RAULT and compared it with conventional clinical criteria (ClinC).
METHODS
We prospectively studied adult patients who underwent LT for ALD between 2008 and 2023. Since 2020, RAULT has been assessed quarterly using both ClinC and PEth (cut-off > 0.05 µg/L). Discordant results were interpreted using PEth as a biochemical comparator, given its higher objectivity and specificity compared with ClinC, although it was not considered a definitive diagnostic standard.
RESULTS
Among 143 patients (median age 56 years; 29% female; median post-LT follow-up 72 months), during a 3-year comparative study interval, RAULT was identified in 46 patients (32.2%) by PEth and in 69 patients (48.3%) by ClinC. Concordance between the two methods was observed in 98 cases (68.5%): in 63 cases (44.0%) for absence of RAULT and in 35 cases (24.5%) for presence of RAULT. Discordance occurred in 45 cases (31.5%), including 34 ClinC-positive/PEth-negative cases (23.8%) and 11 ClinC-negative/PEth-positive cases (7.7%). Quarterly and semi-annual PEth testing yielded comparable overall RAULT detection rates; however, quarterly testing identified a higher proportion of severe RAULT (16.1% vs. 12.6%). Time since LT independently predicted RAULT according to PEth (OR = 1.17; 95% CI 1.08-1.27; p = 0.0002).
CONCLUSIONS
Clinical criteria may overestimate the occurrence of RAULT after liver transplantation. Quarterly or semi-annual PEth testing provides additional objective insight into post-transplant alcohol use dynamics and may enhance monitoring of patients with AUD following LT.
References
Skladany L, Adamcova Selcanova S, Koller T. Alcohol use relapse following liver transplantation for alcoholic liver disease. Ann Transplant. 2019;24:359–366. doi.org
Burra P, Sensolo M, Adam R, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant. 2010;10(1):138–148. doi.org
Im GY, Cameron AM, Lucey MR. Liver transplantation for alcoholic hepatitis. J Hepatol. 2019;70(2):328–334. doi.org . (PMID: 30658734)
Beresford TP, Everson GT. Liver transplantation for alcoholic liver disease: bias, beliefs, 6-month rule, and relapse--but where are the data? Liver Transpl. 2000;6(6):777–778. doi.org . (PMID: 11084067)
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no conflicts of interest relevant to this manuscript.
MeSH
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
Copyright
© 2026. The Author(s).